Assessing the risk of refractory disease in iTTP
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16947
Abstract: Immune thrombocytopenic purpura (iTTP) is caused by a severe acquired deficiency in the metalloprotease ADAMTS13 and is one of several disease processes manifesting as a thrombotic microangiopathy (TMA). While therapeutic plasma exchange (TPE) has proven… read more here.
Keywords: risk; refractory disease; disease; risk refractory ... See more keywords
First use of the anti‐VWF nanobody caplacizumab to treat iTTP in pregnancy
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17833
Abstract: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare thrombotic microangiopathy (TMA), caused by autoantibodies against the metalloproteinase ADAMTS13. Subsequent accumulation of ultra-large von Willebrand factor (VWF) multimers induces platelet agglutination and microvascular thrombosis. Pregnancy is… read more here.
Keywords: adamts13; patient; pregnancy; first use ... See more keywords
Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113762
Abstract: Background. Deficient ADAMTS13 activity (TS13:act 50%. However, also iTTP patients in remission with a persistent (50%, 10-50%,50% in 41, 10-50% in 14 and 50%, confirming our previous results. Interestingly, ADAMTS13 was open in 93% and… read more here.
Keywords: adamts13; conformation; speakers bureau; anti adamts13 ... See more keywords
Race, Rituximab, and Relapse in TTP.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016640
Abstract: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy causing ischemic organ impairment. Blacks are overrepresented in iTTP cohorts in the United States but racial disparities in iTTP outcomes and response… read more here.
Keywords: black patients; race rituximab; ittp; race ... See more keywords
Caplacizumab as frontline therapy in addition to standard treatment in iTTP
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022009448
Abstract: We read with interest the meta-analysis performed by Djulbegovic et al about the use of caplacizumab as a treatment for patients with immune thrombotic thrombocytopenic purpura (iTTP). 1 We respectfully disagree with some of the… read more here.
Keywords: addition; ittp; caplacizumab frontline; standard ... See more keywords
Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2020.588526
Abstract: Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder managed with plasma exchange (PLEX) and steroids. Addition of rituximab (RTX) to initial disease treatment has been shown to lower future relapse rates. Information… read more here.
Keywords: remission; group; duration; immune thrombotic ... See more keywords
Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2023.1137019
Abstract: Advances in diagnosis and treatment have dramatically improved survival of acute immune thrombotic thrombocytopenic purpura (iTTP) and iTTP has evolved from an acute fatal condition to a chronic relapsing disorder. In addition to the risk… read more here.
Keywords: long term; ittp; immune thrombotic; thrombotic thrombocytopenic ... See more keywords